- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 238
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 456906, Placebo, Semaglutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 31
- States / cities
- Huntington Park, California • Los Angeles, California • Northridge, California + 27 more
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Interventions
- RDX-002, Placebo
- Drug
- Lead sponsor
- Response Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pregnancy, Obesity, Overweight
- Interventions
- No Intervention
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 728 participants
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Obesity
- Interventions
- Nimacimab injection, Nimacimab placebo injection, semaglutide injection, Nimacimab 300 mg injection
- Biological · Combination Product
- Lead sponsor
- Skye Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Anniston, Alabama • Walnut Creek, California • Waterbury, Connecticut + 13 more
- Conditions
- Early Alzheimer´s Disease
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus], Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- IcoSema, Insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 66
- States / cities
- Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide), Placebo (cagrilintide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Fresno, California • Los Alamitos, California + 19 more
- Conditions
- Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atrial Fibrillation, Obesity, Overweight
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
- Interventions
- Semaglutide 1.0 mg
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Early Alzheimer's Disease
- Interventions
- Semagludtide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 96
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 76 more
- Conditions
- Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Interventions
- Semaglutide Pill, Fresh organic vegetables
- Drug · Dietary Supplement
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Obesity, Obese, Overweight or Obesity
- Interventions
- Bimagrumab, Semaglutide, Placebo
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
- Conditions
- Adult Obesity, Weight Management
- Interventions
- ECC4703, Placebo, Semaglutide
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Alamitos, California + 11 more
- Conditions
- Overweight or Obesity, Atrial Fibrillation
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Chicago, Illinois
- Conditions
- Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor
- Interventions
- Ozempic®
- Drug
- Lead sponsor
- John Bauer
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Obesity
- Interventions
- Placebo, VTX3232 30 mg, Placebo in combination with semaglutide, VTX3232 30 mg in combination with semaglutide
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Lake Forest, California • Long Beach, California + 9 more
- Conditions
- Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
- Interventions
- Semaglutide 2.4mg, Placebo
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California